Speculation Grows On Potential Big Pharma Buyout Of Mirati

Deal Could Hinge On New Readouts

 
• By Andrew McConaghie

Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.

Mirati Therapeutics
Mirati is chasing Amgen in the KRAS GC12 inhibitor market, and expects to gain its first US approval by mid-December.

More from Business

More from Scrip